SEC Form 4 · accession 0000899243-15-010542
KalVista Pharmaceuticals, Inc. · KALV
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
David Renzi
Officer — President & CEO · Director
Period of report
Dec 30, 2015
Accepted (ET)
Dec 31, 2015 · 4:05 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001348911
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Dec 30, 2015 | M | 10,000 | $0.56 | A | 10,000 | D | |
| Common StockF2 | Dec 30, 2015 | S | 10,000 | $3.70 | D | 0 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F3 | $0.56 | Dec 30, 2015 | M | 10,000 | D | — | Jun 6, 2023 | Common Stock | 10,000 | 515,825 | D |
Explanation of responses
- F1The sales reported on this Form 4 were effected pursuant to a trading plan adopted pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended.
- F2Represents the weighted-average price at which shares were sold within a range between $3.65 and $3.725, inclusive. The reporting person hereby undertakes to provide, upon request, to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- F3The option for 525,825 shares of common stock was granted on 6/6/2013. 1/4 of the option grant was fully vested and exercisable on 6/6/2014, and 1/48 of the option grant vests and becomes exercisable each month thereafter.